MEDANTA1,457.00

Global Health Ltd.

· Pharma & Health
₹ CrorePeersMAXHEALTHAPOLLOHOSPFORTISGLAXOANTHEMAJANTPHARMIPCALABABBOTINDIAMcap ₹39,148 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
MEDANTA
FY26
MAXHEALTH
FY26
APOLLOHOSP
FY26
FORTIS
FY26
Peer
Median
Valuation — at last close
P/E70.35×69.66×65.86×65.36×65.86× +7%
P/B9.83×9.36×12.82×6.70×9.36× +5%
EV/EBITDA43.75×46.08×34.95×33.84×34.95× +25%
Market Cap₹39,148 Cr₹1.01L Cr₹1.28L Cr₹68,097 Cr₹1.01L Cr -61%
Growth
Revenue CAGR 3Y17.85%22.43%14.94%13.17%14.94% +19%
Revenue CAGR 5Y27.30%19.03%17.76%19.03%
Net Income CAGR 3Y19.33%9.34%33.35%18.91%18.91% +2%
Revenue YoY (latest Q)26.50%16.70%20.56%17.46%17.46% +52%
Net Income YoY (latest Q)-1.09%4.87%38.41%2.26%4.87% -122%
Profitability
EBITDA Margin20.84%26.79%14.94%22.84%22.84% -9%
Net Income Margin12.56%17.23%7.94%11.66%11.66% +8%
Return on Common Equity13.97%13.42%19.47%10.25%13.42% +4%
Return on Capital Employed13.20%11.94%18.41%11.81%11.94% +11%
Return on Assets9.38%8.37%9.02%6.67%8.37% +12%
Credit & Quality
Total Debt/Equity0.30×0.32×0.57×0.28×0.32× -6%
Interest Coverage8.80×7.64×6.44×5.20×6.44× +37%
Scale — latest FY
Revenue / Total Income₹4,410 Cr₹8,373 Cr₹25,229 Cr₹9,128 Cr₹9,128 Cr -52%
Net Income₹554 Cr₹1,442 Cr₹2,003 Cr₹1,064 Cr₹1,442 Cr -62%
Total Assets₹5,905 Cr₹17,231 Cr₹22,197 Cr₹15,966 Cr₹17,231 Cr -66%
EPS₹20.71₹14.83₹135.04₹13.8₹14.83 +40%
Book Value per Share₹148.29₹110.43₹693.64₹134.69₹134.69 +10%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.